# Summary of Consolidated Financial Results for the First Quarter of Fiscal Year Ending March 31, 2018 

Name of Listed Company:
Securities Code Number:
Corporate Representative / Title
Contact Representative / Title Makoto Kawamura/ Corporate Officer, Joint General Manager, Corporate Development and Planning Division and General Manager, Public and Investor Relations Office

TEL: +81-3-6838-2803
Scheduled Submission Date for Quarterly Report: August 14, 2017
Quarterly Supplemental Explanatory Material Prepared: None
Quarterly Results Briefing Held: None
(Amounts are truncated to the nearest million yen.)

1. Consolidated Results of Operations during the First Quarter of Fiscal Year ending March 31, 2018 (from April 1, 2017 to June 30, 2017)
(1) Consolidated Results of Operations (Cumulative)
(Percentages indicate the rate of change compared with the preceding fiscal year.)

|  | Net Sales |  | Operating Income |  | Ordinary Income |  | Profit attributable to owners of parent |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Million yen | \% | Million yen | \% | Million yen | \% | Million yen | \% |
| First Quarter ended June 2017 | 299,279 | -4.8 | 2,431 | -35.2 | 3,856 | -27.1 | 2,305 | -34.2 |
| First Quarter ended June 2016 | 314,333 | 6.5 | 3,753 | 39.6 | 5,293 | 22.8 | 3,503 | 157.8 |

(Note)Comprehensive income: First Quarter ended June 2017: 3,028 million yen (-27.8\%); First Quarter ended June 2016: 4,196 million yen (147.4\%)

|  | Current Net Income <br> per Share | Current Net Income <br> per Share - Diluted |
| :--- | :---: | :---: | :---: |
| First Quarter ended June 2017 | $33.56 \quad$ Yen | Yen |
| First Quarter ended June 2016 | 51.06 | 30.47 <br> 46.42 |

(2) Consolidated Financial Position

|  | Total Assets | Net Assets | Shareholder's Equity <br> Ratio |
| :--- | :---: | :---: | :---: |
| First Quarter ended June 2017 | Million yen | Million yen | \% |
| Fiscal Year ended March 2017 | 612,917 | 189,666 | 30.9 |
|  | 598,871 | 188,271 | 31.4 |

(Reference) Shareholder’s equity: First Quarter ended June 2017: 189,497 million yen; Fiscal Year ended March 2017: 188,126 million yen
2. Historical Payment of Dividends

|  | Annual Cash Dividend per Share |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
|  | End of <br> first quarter | End of <br> second quarter | End of <br> third quarter | Year-end | Annual |
| Fiscal Year ended March 2017 | $-\quad$ Yen | Yen | $-\quad$ Yen | Yen | Yen |
| Fiscal Year ending March 2018 | - | 15.00 | - | 15.00 | 30.00 |
| Fiscal Year ending March 2018 <br> (Projected) |  | 15.00 | - | 15.00 | 30.00 |

(Note)Revision of the dividend forecasts most recently announced: None
3. Projected Consolidated Results of Operations during Fiscal Year ending March 2018
(from April 1, 2017 to March 31, 2018)
(The figures in percentages indicate changes from the preceding fiscal year for the year-end and changes from the preceding interim term for the current first half.)

|  | Net Sales |  | Operating Income |  | Ordinary Income |  | Profit attributable to owners of parent |  | Net Income per Share |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Million yen | \% | Million yen | \% | Million yen | \% | Million yen | \% | Yen |
| First half | 573,000 | -6.9 | 5,000 | -34.6 | 7,200 | -31.9 | 4,000 | -41.9 | 58.18 |
| Full year | 1,186,000 | -3.7 | 14,300 | 0.4 | 18,700 | -5.8 | 10,300 | -27.6 | 149.81 |

(Note)Revision of consolidated projected results of operations most recently announced: None

## ※ Notes

(1) Changes in material subsidiaries during the first quarter ended June 2017: N.A.
(Changes in special subsidiaries accompanying a change in the scope of consolidation)
Inclusion - (Company name: ) Exclusion -(Company name: )
(2) Application of accounting process which is peculiar to the compilation of consolidated quarterly financial statements: N.A.
(3) Changes in accounting policies and changes in accounting estimates, and correction and restatement
(i) Changes in accounting policies with revisions in the accounting standards, etc.: N.A.
(ii) Changes in accounting policies other than those under the item (i): N.A.
(iii) Changes in the accounting estimates: N.A
(iv) Correction and Restatement: N.A
(4) Number of shares outstanding (Common stock)
(i) Number of shares outstanding at end of fiscal year (Including common stock for treasury)
(ii) Number of treasury stocks at end of fiscal year
(iii) The average number of shares during the first quarter

| First Quarter <br> ended June 2017 | 78,270,142 | Fiscal Year ended <br> March 2017 | $78,270,142$ |
| :--- | :---: | :--- | :---: |
| First Quarter <br> ended June 2017 | $9,805,137$ | Fiscal Year ended <br> March 2017 | $9,518,069$ |
| First Quarter <br> ended June 2017 | $68,717,366$ | First Quarter <br> ended June 2016 | $68,612,155$ |

*This quarterly earnings report is exempt from the quarterly review.

* Explanation of Appropriate Use of Performance Projections and Other Items Requiring Special Description

Any forward-looking statements contained in this report, including performance projections, are based on information currently available to the Company as well as certain assumptions that the Company determined to be rational at the time of the release of this report, and it is not intended that the Company undertake to achieve such results. Actual results may differ significantly from the projections above, due to a variety of factors. Please refer to Qualitative Information on Projected Consolidated Results of Operations on page 3 of this report (the Attached Document) for the suppositions on which the performance projections are based and points that have to be borne in mind for the use of such projections.

1. Qualitative Information on Financial Results for the First Quarter ended June2016 ..... $\cdot 2$
(1)Explanation of Management Results ..... $\cdot 2$
(2) Explanation of Financial Position ..... - 3
(3) Explanation of Projections of Consolidated Operating Results for Fiscal Year ending March 2018 .....  3
2. Quarterly Consolidated Financial Statements and Main Notes .....  .4
(1) Quarterly Consolidated Balance Sheets ..... 4
(2) Quarterly Consolidated Profit and Loss Statement and Quarterly Consolidated Statements of Comprehensive Income ..... 6
Quarterly Consolidated Profit and Loss Statement ..... - 6
Quarterly Consolidated Statements of Comprehensive Income ..... - 8
(3) Notes Concerning Quarterly Consolidated Financial Statements ..... 9
(Notes Concerning Premise of a Going Business) ..... 9
(Notes Concerning Material Changes in Shareholders’ Equity) ..... $\cdot 9$
(Segmental Information) ..... 10
3. Qualitative Information on Financial Results for the First Quarter ended June 2017
(1)Explanation of Management Results

During the first quarter under review, the prescription pharmaceuticals market saw $3.2 \%$ negative growth compared to the same period of the previous year. While the results of the Company fell year on year below the market average due to a decrease in sales of the curative drugs for hepatitis $C$, the progress to projections exceeded the standard.
The Group has, as a corporate group engaged in the areas of medical care, health care, and nursing care, continued to develop and propose customer support systems to offer solutions to problems faced by patients, medical institutions and specialists etc. in the fields of home healthcare and nursing care. In addition, the Company has tackled to develop service and systems including new themes such as enhancement of function as a healthcare support pharmacy and establishment of a community comprehensive healthcare system, thereby promoting a shift to a business model that focuses on value-added services. In anticipation of the era in which generic drugs account for $80 \%$ or more of the off-patent pharmaceuticals market on a volume basis, KYOSOMIRAI PHARMA, which was established in November 2016, released 2 ingredients/11 products listed on the NHI drug prices as a supplement in June 2017, accordingly offering 4 ingredients/ 14 products as "KYOSOMIRAI PHARMA" brand products.
The Company's operating results for the consolidated cumulative first quarter of the fiscal year ending March 2018 recorded 299,279 million yen for net sales (a decrease of $4.8 \%$ on a year-on-year basis), 2,431 million yen for operating income (a decrease of $35.2 \%$ on a year-on-year basis), 3,856 million yen for ordinary income (a decrease of $27.1 \%$ on a year-on-year basis), and 2,305 million yen for net income attributable to the shareholders of the parent company (a decrease of $34.2 \%$ on a year-on-year basis).
The progress rate compared to the forecasts for the first half of the fiscal year ending March 2018 is net sales of $52.2 \%$, operating income of $48.6 \%$, ordinary income of $53.6 \%$, and net income attributable to the shareholders of the parent company of $57.6 \%$.

The outline of operating results by business segment is as follows:
In the pharmaceutical wholesaling business, completing an absorption-type merger of Godo Toho Co., Ltd. into TOHO PHARMACEUTICAL CO., LTD. in April, 2017 and newly establishing the Kansai branch, we reinforced a prompt cooperation structure as well as strengthened our operating base by increasing the number of members of the Kyoso Mirai Group in Pharmacy. Furthermore, aiming at spreading our customer support systems at early stage, we made efforts to increase the number of contracts especially for "Byouin-Navi", "initial examination reservation service" and "ENIFvoice SP".
As a result, in the first quarter of the current fiscal year, the pharmaceutical wholesaling business posted net sales of 286,808 million yen (a decrease of $5.3 \%$ on a year-on-year basis) and segment income (operating income) of 2,221 million yen (a decrease of $45.1 \%$ on a year-on-year basis).
In the dispensing pharmacy business, we endeavored to improve profitability by responding to the dispensing fee revision and increasing management efficiency through standardization of store operations and consolidation of some operations into the headquarters. As a result, in the first quarter of the current fiscal year, the dispensing pharmacy business posted net sales of 24,147 million yen (an increase of $2.8 \%$ on a year-on-year basis) and segment income (operating income) of 662 million yen (operating loss of 118 million yen in the same period of the previous fiscal year).
In the SMO operations, net sales for the first quarter ended June 2017 amounted to 75 million yen (a decrease of $18.9 \%$ on a year-on-year basis) and segment income (operating income) was 20 million yen (a decrease of $39.9 \%$ on a year-on-year basis).
In the information equipment sales operations, net sales for the first quarter ended June 2017 totaled 281 million yen (an increase of $32.6 \%$ on a year-on-year basis), with a segment loss (operating loss) of 58 million yen.
(Note) Segment net sales include inter-segment transactions.
(2) Explanation of Financial Position
(Assets)
Current assets increased $2.7 \%$ from the end of the previous consolidated fiscal year to 438,509 million yen with an increase in cash and deposits of 7,401 million yen, and an increase in merchandise and finished goods of 4,713million yen.
Noncurrent assets increased $1.5 \%$ from the end of the previous consolidated fiscal year to 174,407 million yen with an increase in investment securities of 3,860 million yen, a decrease in property, plant and equipment of 475 million yen and a decrease in goodwill of 507 million yen.
As a result, consolidated net assets increased $2.3 \%$ from the end of the previous consolidated fiscal year, to 612,917million yen.
(Liabilities)
Current liabilities increased $3.6 \%$ from the end of the previous consolidated fiscal year to 381,939 million yen with an increase in notes and accounts payable-trade of 12,315 million yen.
Noncurrent liabilities decreased $1.3 \%$ from the end of the previous consolidated fiscal year, to 41,310 million yen with a decrease in long-term loans payable of 395 million yen.
As a result, total liabilities increased $3.1 \%$ from the end of the previous consolidated fiscal year, to 423,250 million yen.
(Net assets)
Total net assets increased $0.7 \%$ from the end of the previous consolidated fiscal year to 189,666 million yen with an increase in retained earnings of 1,274 million yen, an increase in valuation difference on available-for-sale securities of 722 million yen, and an increase in treasury stocks of 625 million yen.
(3) Explanation of Projections of Consolidated Operating Results for Fiscal Year ending March 2018

There are no changes in the projected consolidated results of operations for the cumulative second quarter of the fiscal year ending March 2018 and the full-term of the fiscal year published on May 11, 2017.
2. Quarterly Consolidated Financial Statements and Main Notes Concerning (1) Quarterly Consolidated Balance Sheets
(Unit: million yen)

|  | Previous consolidated fiscal year (As of March 31, 2017) | End of this consolidated first quarter <br> (As of June 30, 2018) |
| :---: | :---: | :---: |
| Assets |  |  |
| Current assets |  |  |
| Cash and deposits | 31,966 | 39,368 |
| Notes and accounts receivable-trade | 284,205 | 283,567 |
| Merchandise and finished goods | 73,575 | 78,289 |
| Other | 37,616 | 37,591 |
| Allowance for doubtful accounts | -312 | -307 |
| Total current assets | 427,052 | 438,509 |
| Noncurrent assets |  |  |
| Property, plant and equipment | 86,371 | 85,896 |
| Intangible assets |  |  |
| Goodwill | 4,300 | 3,792 |
| Other | 2,998 | 2,854 |
| Total intangible assets | 7,298 | 6,647 |
| Investments and other assets |  |  |
| Investment securities | 68,781 | 72,642 |
| Other | 11,972 | 11,821 |
| Allowance for doubtful accounts | -2,605 | -2,600 |
| Total investments and other assets | 78,148 | 81,863 |
| Total noncurrent asset | 171,818 | 174,407 |
| Total assets | 598,871 | 612,917 |


| Liabilities |  |  |
| :---: | :---: | :---: |
| Current liabilities |  |  |
| Notes and accounts payable-trade | 349,039 | 361,355 |
| Short-term loans payable | 4,216 | 4,012 |
| Income taxes payable | 3,020 | 1,725 |
| Provision for bonuses | 3,506 | 5,178 |
| Provision for directors' bonuses | 75 | 27 |
| Provision for sales returns | 324 | 315 |
| Asset retirement obligations | - | 1 |
| Other | 8,575 | 9,322 |
| Total current liabilities | 368,758 | 381,939 |
| Noncurrent liabilities |  |  |
| Bonds payable | 15,041 | 15,037 |
| Long-term loans payable | 1,962 | 1,567 |
| Provision for retirement benefits | 1,786 | 1,802 |
| Asset retirement obligations | 1,078 | 1,076 |
| Negative goodwill | 49 | 42 |
| Other | 21,923 | 21,784 |
| Total noncurrent liabilities | 41,841 | 41,310 |
| Total liabilities | 410,599 | 423,250 |
| Net assets |  |  |
| Shareholders' equity |  |  |
| Capital stock | 10,649 | 10,649 |
| Capital surplus | 47,856 | 47,856 |
| Retained earnings | 128,123 | 129,397 |
| Treasury stock | -16,051 | -16,677 |
| Total shareholders' equity | 170,577 | 171,226 |
| Accumulated other comprehensive income |  |  |
| Valuation difference on available-for-sale securities | 21,836 | 22,558 |
| Revaluation reserve for land | -4,287 | -4,287 |
| Total accumulated other comprehensive income | 17,548 | 18,271 |
| Subscription rights to shares | 145 | 168 |
| Total net assets | 188,271 | 189,666 |
| Total liabilities and net assets | 598,871 | 612,917 |

(2)Quarterly Consolidated Profit and Loss Statement and Quarterly Consolidated Statements of Comprehensive Income Quarterly Consolidated Profit and Loss Statement [Cumulative period for the consolidated first quarter]
(Unit: million yen)

|  | Cumulative period for previous consolidated first quarter (from April 1, 2016 to June 30, 2016) | Cumulative period for this consolidated first quarter (from April 1, 2017 to June 30, 2017) |
| :---: | :---: | :---: |
| Net sales | 314,333 | 299,279 |
| Cost of sales | 286,568 | 273,069 |
| Gross profit | 27,765 | 26,210 |
| Selling, general and administrative expenses |  |  |
| Directors' compensations, salaries and allowances | 10,398 | 10,343 |
| Provision for bonuses | 1,843 | 1,727 |
| Provision for directors' bonuses | 19 | 17 |
| Retirement benefit expenses | 57 | 53 |
| Welfare expenses | 1,953 | 1,961 |
| Vehicle expenses | 263 | 261 |
| Provision of allowance for doubtful accounts | -8 | -11 |
| Depreciation | 1,102 | 1,085 |
| Amortization of goodwill | 551 | 507 |
| Rent expenses | 1,724 | 1,760 |
| Taxes and dues | 465 | 459 |
| Expense before deduction of temporary consumption tax payment | 1,364 | 1,333 |
| Other | 4,275 | 4,277 |
| Total selling, general and administrative expenses | 24,011 | 23,778 |
| Operating income | 3,753 | 2,431 |
| Non-operating income |  |  |
| Interest income | 12 | 13 |
| Dividend income | 438 | 477 |
| Commission fee | 739 | 709 |
| Amortization of negative goodwill | 6 | 6 |
| Equity in earnings of affiliates | 1 | 2 |
| Other | 542 | 401 |
| Total non-operating income | 1,740 | 1,612 |
| Non-operating expenses |  |  |
| Interest expenses | 24 | 11 |
| Expenses of real estate rent | 136 | 90 |
| Settlement package | - | 59 |
| Other | 40 | 26 |
| Total non-operating expenses | 201 | 187 |
| Ordinary income | 5,293 | 3,856 |


|  | Cumulative period for <br> previous consolidated first quarter <br> (from April 1, 2016 to June 30, 2016) | Cumulative period for <br> this consolidated first quarter <br> from April 1, 2017 to June 30, 2017) |
| :--- | ---: | ---: | ---: |
| Extraordinary income |  |  |
| Gain on sales of noncurrent assets | 135 | 0 |
| Gain on sales of investment securities | - | 0 |
| Other | 7 | 1 |
| Total extraordinary income | 143 | 2 |
| Extraordinary loss |  | 30 |
| Loss on disposal of noncurrent assets | 19 | 3 |
| Other | - | 34 |
| Total extraordinary loss | 19 | 3,823 |
| Income before income taxes | 5,417 | 1,973 |
| Income taxes-current | 2,399 | -455 |
| Income taxes-deferred | -485 | 1,518 |
| Total income taxes | 1,913 | 2,305 |
| Current net income | 3,503 | 2,305 |
| Profit attributable to owners of parent | 3,503 |  |

Quarterly Consolidated Statements of Comprehensive Income [Cumulative period for the consolidated first quarter]
(Unit: million yen)

|  | Cumulative period for previous consolidated first quarter (from April 1, 2016 to June 30, 2016) | Cumulative period for this consolidated first quarter (from April 1, 2017 to June 30, 2017) |
| :---: | :---: | :---: |
| Current net income | 3,503 | 2,305 |
| Other comprehensive income |  |  |
| Valuation difference on available-for-sale securities | 705 | 705 |
| Share of other comprehensive income of associates accounted for using equity method | -12 | 17 |
| Total other comprehensive income | 692 | 722 |
| Comprehensive income | 4,196 | 3,028 |
| Comprehensive income attributable to |  |  |
| Comprehensive income attributable to owners of the parent | 4,196 | 3,028 |
| Comprehensive income attributable to non-controlling interests | - | - |

(3)Notes of Quarterly Consolidated Financial Statements
(Notes Concerning Premise of a Going Business)
Not applicable.
(Notes concerning Material Changes in Shareholders' Equity)
Cumulative period for this consolidated first quarter (from April 1, 2017 to June 30, 2017)
Not applicable

## (Segmental Information)

I Cumulative period for previous consolidated first quarter (from April 1, 2016 to June 30, 2016)

1. Information about sales and profit or loss by reportable segment

|  | Reportable segments |  |  |  |  | Adjustments (million yen) (Note 1) | Amount on the quarterly consolidated profit and loss statement (million yen) (Note2) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Pharmaceutical Wholesaling (million yen) | Dispensing Pharmacy (million yen) | SMO (million yen) | Information equipment sales (million yen) | Total (million yen) |  |  |
| Net Sales |  |  |  |  |  |  |  |
| (1) Net sales to external customers | 290,674 | 23,406 | 92 | 160 | 314,333 | - | 314,333 |
| (2) Inter-segment internal net sales or transfers | 12,184 | 93 | - | 52 | 12,330 | -12,330 | - |
| Total | 302,859 | 23,499 | 92 | 212 | 326,663 | -12,330 | 314,333 |
| Segment profit | 4,043 | -118 | 34 | -69 | 3,888 | -134 | 3,753 |

(Note) 1.The amount of the adjustments for segment profits or losses shows the elimination of internal transactions and unrealized profit.
2. The amounts for income or losses in the reportable segments were subsequently adjusted with the amount of operating income on the quarterly consolidated profit and loss statement.
2. Information about impairment losses on noncurrent assets or goodwill by each business segment Not applicable

II Cumulative period for this consolidated first quarter (from April 1, 2017 to June 30, 2017)

1. Information about sales and profit or loss by reportable segment

|  | Reportable segments |  |  |  |  | Adjustments (million yen) <br> (Note 1) | Amount on the quarterly consolidated profit and loss statement (million yen) (Note2) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Pharmaceutical Wholesaling (million yen) | Dispensing <br> Pharmacy (million yen) | SMO (million yen) | $\begin{aligned} & \text { Information } \\ & \text { equipment } \\ & \text { sales } \\ & \text { (million yen) } \end{aligned}$ | Total (million yen) |  |  |
| Net Sales |  |  |  |  |  |  |  |
| (1) Net sales to external customers | 274,963 | 24,051 | 75 | 189 | 229,279 | - | 299,279 |
| (2) Inter-segment internal net sales or transfers | 11,845 | 95 | - | 92 | 12,034 | -12,034 | - |
| Total | 286,808 | 24,147 | 75 | 281 | 311,313 | -12,034 | 299,279 |
| Segment profit | 2,221 | 662 | 20 | -58 | 2,846 | -414 | 2,431 |

(Note) 1.The amount of the adjustments for segment profits or losses shows the elimination of internal transactions and unrealized profit.
2. The amounts for income or losses in the reportable segments were subsequently adjusted with the amount of operating income on the quarterly consolidated profit and loss statement.
2. Information about impairment losses on noncurrent assets or goodwill by each business segment Not applicable

